title: [Bone metastases in lung cancer].
abstract: The skeleton is one of the most common sites of metastasis in patients with lung cancer. It has been reported that the incidence of bone metastases in lung cancer patients is approximately 30-40%, and the median survival time (MST) of patients with such metastases is 6-7 months. Metastatic bone disease leads to various complications or skeletal related events (SREs), including pain, pathologic fracture, vertebral deformity and collapse, spinal cord compression, and hypercalcemia of malignancy. These events often lead to rapid deterioration in quality of life (QOL). The fundamental treatment for bone metastasis from advanced lung cancer is disease control by systemic chemotherapy. So the prevention and treatment of bone metastases is mainly dependent on an effective treatment against lung cancer itself. As a direct treatment for bone metastases, radiation therapy, surgery and bisphosphonates are the main ways.
authors: Shizuoka Cancer Center, Division of Thoracic Oncology.
authors: Asuka
authors: A
authors: Tsuya
authors: Masahiro
authors: M
authors: Fukuoka
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000209:etiology; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy*; D004164:Diphosphonates / Q000627:therapeutic use; D019583:Dose Fractionation, Radiation; D005598:Fractures, Spontaneous / Q000209:etiology; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology; D008175:Lung Neoplasms / Q000473:pathology* / Q000628:therapy; D019637:Orthopedic Procedures; D010146:Pain / Q000209:etiology; D013117:Spinal Cord Compression / Q000209:etiology
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates